Study on the effect of the original exercise program on muscle strength, muscle mass, and metabolic parameters
Not yet recruiting
- Conditions
- Type2 diabetes
- Registration Number
- jRCT1050210193
- Lead Sponsor
- Hitoshi Nishizawa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Type 2 diabetic patients admitted to the Department of Diabetes, Endocrinology, and Metabolism, Osaka University Hospital (regardless of gender), who meet the following criteria
- Patients aged 20 to 74 years
- Patients diagnosed with type 2 diabetes by the doctors
- Patients who have agreed to participate in the program
Exclusion Criteria
- Patients with type 1 diabetes or secondary diabetes
- Fasting plasma glucose; 250mg/dl or more
- Resting blood pressure; 180/110mmHg or more
- Diabetic nephropathy with stage 3 or more (urinary albumin/creatinine ratio; 300 mg/g Cr or more or persistent proteinuria)
- Severe neuropathy (sensory and autonomic neuropathy)
- Unstable diabetic retinopathy such as preproliferative or proliferative retinopathy
- Unstable macroangiopathy such as cardiovascular disease and peripheral arterial disease
- Severe liver damage (decompensated cirrhosis, etc.)
- Heart failure (NYHA; II or more or patients on limited physical activity)
- Patients at high risk of hypoglycemia
- Patients whose condition is thought to worsen by whole body vibration (e.g. dizziness, etc.)
- Patients who are at risk of falling and are judged to have difficulty in performing whole body vibration
- Female patients who are pregnant or potentially pregnant and are lactating
- Patients who are judged by the doctors to be inappropriate for participation in the program due to complications (e.g. blindness, decreased ADL, scheduled surgery, uncontrollable active infections, etc.)
- Patients who are difficult for the doctors to assess the effectiveness of the program (e.g. complications of psychiatric disorders or mental disorders, having difficulty in communicating with medical staff, alcohol-dependent / drug-dependent, planning a long trip during the program, opposed by their families, and a rapid weight loss more than 4.5 kg within 3 months, etc.)
- Patients that the primary investigator or the doctors consider to be inappropriate for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method Plasma hypoxanthine (HX), xanthine (Xan), uric acid (UA), and xanthine oxidoreductase (XOR) activity before and after WBV exercise Plasma hypoxanthine (HX), xanthine (Xan), uric acid (UA), and xanthine oxidoreductase (XOR) activity before and after WBV exercise
Body composition Body composition evaluated by In Body
Grip strength Grip strength
Lower limb extension Lower limb extension
Thigh circumference Thigh circumference
- Secondary Outcome Measures
Name Time Method Exercise function test chair-stand test and 6-minute walking distance